<DOC>
	<DOCNO>NCT02783547</DOCNO>
	<brief_summary>This Phase 1 clinical trial evaluate tolerability combination therapy SyB C-1101 ( rigosertib sodium ) Azacytidine determine recommend dose SyB C-1101for Phase 2 trial patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Combination Therapy SyB C-1101 Azacytidine Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion Patients satisfy follow criterion include : 1 . Histologically cytologically diagnose myelodysplastic syndrome ( MDS ) chronic myelomonocytic leukemia ( CMML ) accord World Health Organization ( WHO ) Classification FrenchAmericanBritish ( FAB ) Classification . As patient refractory anemia excess blast transformation ( RAEBt ) , however , peripheral blood white blood cell count ≤ 25,000 /mm3 state disease stabilize least 4 week without treatment . 2 . Recognized Intermediate1 , intermediate2 High accord International Prognostic Scoring System ( IPSS ) . 3 . ≥4 week without treatment effect previous treatment ( antitumor effect ) consider discontinued end previous therapy MDS ( include use erythropoiesisstimulating agent , ESA ) treatment expectation antitumor effect . 4 . Life expectancy ≥3 month . 5 . ≥20 year age ( time acquire consent ) . 6 . Have score 0 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) . 7 . With adequate function major organ ( heart , lung , liver , kidney , etc. ) . Aspartate aminotransferase ( AST ) ( GOT ) : ≤3.0 time upper boundary reference range institution Alanine aminotransferase ( ALT ) ( GPT ) : ≤3.0 time upper boundary reference range institution Total bilirubin : ≤1.5 time upper boundary reference range institution Serum creatinine : ≤1.5 time upper boundary reference range institution ECG : abnormal finding require treatment Echocardiography : abnormal finding require treatment 8 . Voluntarily sign write informed consent form participate study . Exclusion criteria Patients satisfy follow criterion exclude : 1 . With anemia ( haemolytic anaemia , gastrointestinal haemorrhage , etc . ) cause factor MDS . 2 . With history complication active malignant tumor ( exception target disease ) within past 1 year ( basal cell carcinoma squamous cell carcinoma skin ; primary squamous cell carcinoma cervix noninvasive breast cancer allow register ) . 3 . Has receive administration granulocyte colonystimulating factor ( GCSF ) within 14 day examination case registration . 4 . With obvious infectious disease ( include viral infection ) . 5 . With serious complication ( liver failure , renal failure , etc. ) . 6 . With complication serious heart disease ( myocardial infarction , symptomatic ischemic heart disease , unstable angina , etc. ) . With history arrhythmia within 2 year registration arrhythmia require treatment . 7 . With serious gastrointestinal condition ( severe significant nausea/vomiting , diarrhea , etc . ) 8 . Has test positive HBsAg HIV antibody . 9 . With serious bleed tendency ( disseminate intravascular coagulation ( DIC ) , internal hemorrhage , etc. ) . 10 . With accumulation pleural effusion/ascites require treatment paracentesis ect . 11 . With hyponatremia ( serum sodium &lt; 130 mEq/L ) . 12 . Has undergone treatment adrenocortical hormone ( correspond &gt; 10 mg/24 hr prednisolone conversion ) &gt; 2 week within 4 week start administration study drug . 13 . Has undergone treatment another investigational product receive chemotherapy , radiotherapy immunotherapy clinical trial stage within 3 month case registration . 14 . Has recover surgery accompany general anesthesia receive surgery accompany general anesthesia within 3 week case registration . 15 . With properly control hypertension ( systolic pressure ≧160 mmHg diastolic pressure ≧110 mmHg ) . 16 . With properly control epileptic seizure onset epileptic seizure within 3 month case registration . 17 . Has undergone treatment SyB 1101 past . 18 . With history allergic reaction polyethylene glycol , gelatin capsule azacytidine . 19 . Difficult participate study treatment due psychiatric disorder , social condition , ect . 20 . With drug intoxication , narcotic addiction alcohol dependency . 21 . Is pregnant , nurse possibly pregnant . 22 . Is positive pregnancy test ( female patient ) examination case registration . 23 . Not provide consent follow contraceptive measure . Patients avoid sexual intercourse sexual partner use contraceptive method describe following time period : male patient case registration 6 month end administration study drug ; female patient menstruation case registration second menstrual period confirm end administration ; menopausal woman case registration 2 month end administration . ( 1 ) Male patient Must always use condom . For effective contraception , recommend contraceptive method also apply female sexual partner patient . ( 2 ) Female patient Must use least 1 follow contraceptive method . AT time , male partner must use condom . Oral contraceptive ( birth control pill ) Contraceptive injection Contraceptive patch Intrauterine device ( IUD ) Tubal ligation 24 . Disqualified subject study treatment judge principal investigator investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>